Corixa Corporation d.b.a. GlaxoSmithKline
FDA inspection history in Marietta, Pennsylvania, 2022
- 1
- Form 483
Every document, by year
- Form 483
2022: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2022One Form 483, at Marietta, Pennsylvania.
Cited most
Across all Corixa Corporation d.b.a. GlaxoSmithKline observations on file
- 21 CFR 211.130Packaging and labeling operations1
- 21 CFR 211.192Production record review1
The complete Corixa Corporation d.b.a. GlaxoSmithKline file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Marietta, Pennsylvania
One Form 483 · 2022 · 2 observations
Latest: Form 483, Mar 4, 2022 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2022-03-04 | 483 Form 483 | Marietta, Pennsylvania | 2 | $99 |
Investigators on these documents
FEI number 30077266770 · most recent document Mar 4, 2022
About Corixa Corporation d.b.a. GlaxoSmithKline
How many FDA Form 483s has Corixa Corporation d.b.a. GlaxoSmithKline received?
FDA Intel has 1 Form 483 on file for Corixa Corporation d.b.a. GlaxoSmithKline; the most recent is dated Mar 4, 2022.
When was Corixa Corporation d.b.a. GlaxoSmithKline last inspected by FDA?
The most recent FDA inspection document on file for Corixa Corporation d.b.a. GlaxoSmithKline is a Form 483 dated Mar 4, 2022, for the site in Marietta, Pennsylvania.
What did FDA cite at Corixa Corporation d.b.a. GlaxoSmithKline?
The regulations cited most in the observations on file for Corixa Corporation d.b.a. GlaxoSmithKline are 21 CFR 211.130 (Packaging and labeling operations), 1 time; 21 CFR 211.192 (Production record review), 1 time.